Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
BioCryst Pharmaceuticals, Inc is a biotechnology business based in the US. BioCryst Pharmaceuticals shares (BCRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioCryst Pharmaceuticals employs 140 staff and has a trailing 12-month revenue of around USD$49.2 million.
|52-week range||USD$1.38 - USD$6.2862|
|50-day moving average||USD$3.762|
|200-day moving average||USD$4.1341|
|Wall St. target price||USD$8.31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.154|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$49.2 million|
|Gross profit TTM||USD$-62,334,000|
|Return on assets TTM||-43.31%|
|Return on equity TTM||-345.9%|
|Market capitalisation||USD$619.7 million|
TTM: trailing 12 months
There are currently 36.4 million BioCryst Pharmaceuticals shares held short by investors – that's known as BioCryst Pharmaceuticals's "short interest". This figure is 5% up from 34.6 million last month.
There are a few different ways that this level of interest in shorting BioCryst Pharmaceuticals shares can be evaluated.
BioCryst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of BioCryst Pharmaceuticals shares currently shorted divided by the average quantity of BioCryst Pharmaceuticals shares traded daily (recently around 6.1 million). BioCryst Pharmaceuticals's SIR currently stands at 5.94. In other words for every 100,000 BioCryst Pharmaceuticals shares traded daily on the market, roughly 5940 shares are currently held short.
However BioCryst Pharmaceuticals's short interest can also be evaluated against the total number of BioCryst Pharmaceuticals shares, or, against the total number of tradable BioCryst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCryst Pharmaceuticals's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 BioCryst Pharmaceuticals shares in existence, roughly 210 shares are currently held short) or 0.2215% of the tradable shares (for every 100,000 tradable BioCryst Pharmaceuticals shares, roughly 222 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioCryst Pharmaceuticals.
Find out more about how you can short BioCryst Pharmaceuticals stock.
We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $1.38 up to $6.2862. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 2.6663. This would suggest that BioCryst Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.